Salmeterol Orifarm
Long-acting bronchodilator for asthma and COPD maintenance treatment
Quick facts about Salmeterol Orifarm
Key takeaways about Salmeterol Orifarm
- Always use with an inhaled corticosteroid for asthma: Salmeterol must never be used as the sole therapy for asthma. It should always be combined with an inhaled corticosteroid (ICS).
- Not a rescue inhaler: Salmeterol Orifarm does not provide immediate relief during an acute asthma attack. Keep a separate short-acting bronchodilator (e.g., salbutamol) on hand for emergencies.
- Twice-daily dosing: Take one inhalation in the morning and one in the evening, approximately 12 hours apart, for consistent airway protection.
- Watch for paradoxical bronchospasm: In rare cases, increased wheezing may occur immediately after inhalation. If this happens, stop Salmeterol Orifarm and seek medical attention at once.
- Drug interactions matter: Certain medications such as ketoconazole, ritonavir, and beta-blockers can significantly affect the safety and efficacy of salmeterol.
What Is Salmeterol Orifarm and What Is It Used For?
Salmeterol Orifarm is a prescription inhaler containing salmeterol, a long-acting beta-2 adrenergic agonist (LABA) that relaxes the smooth muscles lining the airways in the lungs, making it easier to breathe. It is used for maintenance treatment of asthma alongside an inhaled corticosteroid, and for COPD management.
Salmeterol belongs to a class of medicines called long-acting beta-2 agonists (LABAs). When inhaled, salmeterol binds to beta-2 adrenergic receptors in the smooth muscle of the bronchial tree, causing the muscles to relax and the airways to widen. This bronchodilatory effect makes it significantly easier for air to flow in and out of the lungs, reducing symptoms such as wheezing, shortness of breath, chest tightness, and coughing.
Unlike short-acting bronchodilators such as salbutamol (albuterol) that work within minutes but wear off after 4–6 hours, salmeterol has a slower onset of action—typically 10 to 20 minutes—but its effects last for 12 hours or more. This prolonged duration is what makes it suitable for twice-daily maintenance dosing rather than acute symptom relief. Full bronchodilatory effect is usually achieved within 2 to 3 hours after inhalation.
Salmeterol Orifarm is indicated for the following conditions:
- Asthma maintenance treatment: As add-on therapy to inhaled corticosteroids in patients whose asthma is not adequately controlled with corticosteroids alone. According to the Global Initiative for Asthma (GINA) guidelines, LABAs should always be used in combination with an inhaled corticosteroid, never as monotherapy.
- Chronic Obstructive Pulmonary Disease (COPD): For long-term maintenance treatment to reduce airflow obstruction and improve breathing capacity in patients with COPD, including chronic bronchitis and emphysema.
Salmeterol Orifarm does not provide immediate relief for sudden breathing difficulties. Always carry a separate short-acting bronchodilator (such as salbutamol) as a rescue inhaler for acute asthma attacks. If your symptoms are not adequately controlled, contact your doctor.
If you are being treated for asthma, you should always have both your Salmeterol Orifarm inhaler and your inhaled corticosteroid, and you must use them together as directed. The combination of these two medications provides both long-term airway protection (from salmeterol) and anti-inflammatory control (from the corticosteroid), which together offer the most effective asthma management as recommended by international respiratory guidelines.
What Should You Know Before Taking Salmeterol Orifarm?
Before using Salmeterol Orifarm, inform your doctor about all medical conditions, especially heart disease, thyroid disorders, diabetes, and low potassium levels. Do not use this medicine if you are allergic to salmeterol or any of its ingredients. Always disclose all other medications you are currently taking.
Contraindications
You must not use Salmeterol Orifarm if you are allergic (hypersensitive) to salmeterol or to any of the other ingredients in the medicine. The inactive ingredient in Salmeterol Orifarm is lactose monohydrate, which contains small amounts of milk proteins. If you have a confirmed allergy to milk proteins, you should not use this product. Note that lactose intolerance (difficulty digesting lactose sugar) is different from milk protein allergy and does not typically cause problems with inhaled lactose at the small doses found in dry powder inhalers (up to 12 mg per dose).
Salmeterol Orifarm should not be used as a rescue medication for acute bronchospasm or during an asthma attack. It is intended solely for regular, long-term preventive treatment. Using a LABA for acute episodes is ineffective and may delay appropriate emergency treatment.
Warnings and Precautions
Talk to your doctor, pharmacist, or nurse before using Salmeterol Orifarm if you have any of the following conditions:
- Cardiovascular disease: Salmeterol, like other beta-2 agonists, can stimulate beta-receptors in the heart, potentially causing increased heart rate, elevated blood pressure, or irregular heart rhythm. Patients with coronary artery disease, heart failure, cardiac arrhythmias, or hypertension should be closely monitored.
- Hyperthyroidism (overactive thyroid): Thyroid hormones can enhance the cardiovascular effects of beta-2 agonists. If you have an overactive thyroid, the combination may increase the risk of tachycardia and other cardiac effects.
- Diabetes mellitus: Salmeterol may increase blood glucose levels. Diabetic patients should monitor their blood sugar more frequently when starting treatment and adjust their diabetes medications as needed under medical guidance.
- Hypokalemia (low potassium): Beta-2 agonists can cause a temporary decrease in serum potassium levels. This effect may be exacerbated by concurrent treatment with corticosteroids, diuretics, or theophylline. Low potassium can cause muscle weakness, cramping, and potentially dangerous cardiac arrhythmias.
In rare cases, inhaling Salmeterol Orifarm may trigger paradoxical bronchospasm—a sudden worsening of wheezing and breathing difficulty immediately after taking a dose. If this occurs, stop using Salmeterol Orifarm immediately, use your rescue inhaler (short-acting bronchodilator), and contact your doctor urgently. Do not take another dose of Salmeterol Orifarm until you have been assessed by a healthcare professional.
If you are using Salmeterol Orifarm for asthma, your doctor may wish to review your symptoms at regular intervals. If your asthma worsens or your breathing deteriorates despite regular use, seek medical advice promptly. An increase in rescue inhaler use is often the first sign that asthma control is declining and treatment may need to be adjusted.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, planning to become pregnant, or are breastfeeding, consult your doctor or pharmacist before using Salmeterol Orifarm. The safety of salmeterol during pregnancy has not been extensively studied in controlled clinical trials. However, uncontrolled asthma during pregnancy poses significant risks to both mother and child, including pre-eclampsia, preterm delivery, and low birth weight. The decision to continue or start treatment should be made jointly with your healthcare provider, weighing the benefits of controlled asthma against any potential risks of the medication.
It is not known whether salmeterol passes into breast milk. Your doctor will help you decide whether the benefit of breastfeeding and the benefit of salmeterol treatment together outweigh any potential risks.
Driving and Operating Machinery
The effect of Salmeterol Orifarm on the ability to drive and use machinery has not been formally studied. However, based on the pharmacological profile and reported adverse effects, salmeterol is unlikely to impair your ability to drive or operate machinery. If you experience any side effects such as dizziness or tremor, exercise caution until you know how the medication affects you personally.
Lactose Content
Salmeterol Orifarm contains lactose monohydrate as an excipient, at a level of up to 12 mg per delivered dose. This small amount does not normally cause problems for people with lactose intolerance. However, the lactose excipient does contain trace amounts of milk protein, which may trigger allergic reactions in individuals with confirmed milk protein allergy. If you have a known milk protein allergy, discuss alternative treatment options with your doctor.
How Does Salmeterol Orifarm Interact with Other Drugs?
Salmeterol can interact with several classes of medications, including strong CYP3A4 inhibitors (ketoconazole, ritonavir), beta-blockers, diuretics, and theophylline. Always inform your doctor and pharmacist of all medicines you are taking, including over-the-counter products and herbal supplements.
Drug interactions with salmeterol can be broadly categorized into those that increase the risk of adverse effects and those that reduce the therapeutic benefit of the medication. Understanding these interactions is crucial for safe and effective treatment.
Major Interactions
| Interacting Drug | Type | Effect | Recommendation |
|---|---|---|---|
| Ketoconazole / Itraconazole | CYP3A4 inhibitor | Significantly increases salmeterol plasma levels, raising the risk of cardiovascular side effects including QT prolongation and cardiac arrhythmias | Avoid combination; use alternative antifungal if possible |
| Ritonavir | Strong CYP3A4 inhibitor (HIV protease inhibitor) | Markedly increases salmeterol exposure; reported cases of cardiovascular events | Contraindicated; do not co-administer |
| Erythromycin | Moderate CYP3A4 inhibitor | May increase salmeterol levels, potentially leading to increased heart rate or irregular rhythm | Use with caution; monitor for cardiovascular side effects |
| Beta-blockers (atenolol, propranolol, sotalol) | Beta-adrenergic antagonist | Can reduce or completely block the bronchodilatory effect of salmeterol | Avoid non-selective beta-blockers; cardioselective agents may be used with caution |
| Diuretics (thiazides, loop diuretics) | Potassium-depleting agent | Additive hypokalemia when combined with salmeterol, increasing risk of cardiac arrhythmias and muscle weakness | Monitor serum potassium levels; supplement if needed |
| Theophylline | Methylxanthine bronchodilator | Additive hypokalemia and increased cardiac stimulation | Monitor potassium and heart rate; adjust doses as needed |
| Corticosteroids (systemic) | Anti-inflammatory | May worsen salmeterol-induced hypokalemia | Monitor potassium; consider supplementation in prolonged use |
The interaction with strong CYP3A4 inhibitors is of particular clinical concern. Salmeterol is primarily metabolized by the cytochrome P450 3A4 enzyme (CYP3A4) in the liver. When this enzyme is blocked by medications such as ketoconazole, itraconazole, or the HIV protease inhibitor ritonavir, salmeterol is not broken down efficiently. This leads to greatly elevated blood levels of salmeterol, which can cause serious cardiovascular effects including prolongation of the QTc interval (a marker for potentially fatal heart rhythm disturbances), palpitations, tachycardia, and tremor.
Beta-blockers interact with salmeterol through a pharmacodynamic mechanism—they antagonize the same beta-adrenergic receptors that salmeterol is designed to stimulate. Non-selective beta-blockers (such as propranolol) block both beta-1 (cardiac) and beta-2 (pulmonary) receptors and can essentially negate the bronchodilatory benefit of salmeterol. If a beta-blocker is medically necessary, cardioselective agents (such as bisoprolol or metoprolol) are preferred, though even these should be used with caution and close monitoring in patients with asthma or COPD.
If you are unsure about whether any of your current medications might interact with Salmeterol Orifarm, consult your doctor or pharmacist before starting treatment. Never start, stop, or change the dose of any medicine without your doctor’s advice.
What Is the Correct Dosage of Salmeterol Orifarm?
The standard dose for adults and children aged 4 years and older is one inhalation (50 micrograms) twice daily, morning and evening. Salmeterol Orifarm should be used regularly for optimal benefit and should not exceed two inhalations per day.
Always use Salmeterol Orifarm exactly as your doctor or pharmacist has instructed. Do not change your dose or stop taking the medication without medical advice. Regular use is essential for achieving and maintaining full therapeutic benefit.
Adults
Standard adult dose
1 inhalation (50 µg salmeterol) twice daily – once in the morning and once in the evening, approximately 12 hours apart. Do not exceed 2 inhalations (100 µg) in any 24-hour period. For asthma, always use in combination with an inhaled corticosteroid.
Children
Children aged 4 years and older
1 inhalation (50 µg salmeterol) twice daily – once in the morning and once in the evening. The same dose applies as for adults. Your doctor will have assessed that your child is able to use the inhaler device correctly before prescribing Salmeterol Orifarm.
Children under 4 years
Salmeterol Orifarm is not recommended for children under 4 years of age. Safety and efficacy have not been established in this age group.
Elderly
Elderly patients
No dose adjustment is generally required for elderly patients. However, older adults may be more susceptible to the cardiovascular side effects of beta-2 agonists. Regular monitoring by a healthcare provider is recommended, particularly in patients with underlying cardiac conditions.
| Patient Group | Dose | Frequency | Maximum Daily Dose |
|---|---|---|---|
| Adults | 50 µg (1 inhalation) | Twice daily (morning & evening) | 100 µg (2 inhalations) |
| Children ≥ 4 years | 50 µg (1 inhalation) | Twice daily (morning & evening) | 100 µg (2 inhalations) |
| Children < 4 years | Not recommended | ||
| Elderly | 50 µg (1 inhalation) | Twice daily (morning & evening) | 100 µg (2 inhalations) |
How to Use the Inhaler
Correct inhalation technique is essential for getting the full dose of medication into your lungs. Your doctor, nurse, or pharmacist should demonstrate how to use the device when it is first prescribed, and they should check your technique periodically. Salmeterol Orifarm is a dry powder inhaler (DPI) containing a foil strip with 60 individually sealed blisters of powder. A dose counter on the top of the device shows how many doses remain.
- Open the inhaler: Hold the device in one hand. Slide the thumbgrip in the direction indicated by the arrow as far as it will go until you hear a click. A small hole in the mouthpiece is now exposed.
- Load a dose: Hold the inhaler with the mouthpiece facing you. Slide the lever away from you as far as it will go—you will hear a click. The powder dose is now ready for inhalation. Do not play with the lever, as this wastes doses.
- Breathe out: Hold the inhaler away from your mouth. Breathe out gently and as deeply as is comfortable. Do not breathe out through the inhaler.
- Inhale the dose: Place the mouthpiece between your lips and seal them around it. Breathe in steadily and deeply through the mouthpiece—not through your nose. Remove the inhaler from your mouth, hold your breath for about 10 seconds (or as long as comfortable), then breathe out slowly.
- Close the inhaler: Slide the thumbgrip back towards you as far as it will go. You will hear a click and the lever automatically resets.
You may not taste or feel the powder on your tongue even when you have used the inhaler correctly—this is normal. To clean your inhaler, simply wipe the mouthpiece with a dry tissue. Do not wash it with water.
Children using Salmeterol Orifarm must be supervised to ensure they use correct inhalation technique as described above. If a child cannot use the device effectively, alternative delivery methods should be discussed with the prescribing physician.
Missed Dose
If you forget to take a dose of Salmeterol Orifarm, take it as soon as you remember—unless it is nearly time for your next scheduled dose. In that case, simply skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a forgotten one. Taking extra doses can increase the risk of side effects without providing additional benefit.
Overdose
If you accidentally take more Salmeterol Orifarm than prescribed, or if a child accidentally uses the inhaler, contact your doctor or a poison control centre immediately for assessment and advice. Symptoms of overdose may include:
- Rapid or pounding heartbeat (tachycardia, palpitations)
- Trembling or shaking (tremor)
- Headache
- Dizziness or lightheadedness
Treatment of overdose is generally supportive and symptomatic. In severe cases, medical professionals may administer a cardioselective beta-blocker with caution, while monitoring the patient closely for bronchospasm.
What Are the Side Effects of Salmeterol Orifarm?
Like all medicines, Salmeterol Orifarm can cause side effects, although not everyone gets them. The most common are tremor, palpitations, muscle cramps, and headache. Serious side effects such as paradoxical bronchospasm or severe allergic reactions are very rare. Side effects are usually dose-dependent.
Most side effects associated with salmeterol are a direct result of its pharmacological action on beta-2 adrenergic receptors. While these receptors are predominantly found in the lungs, they are also present in the heart, skeletal muscle, and other tissues, which explains the range of potential adverse effects. In the majority of patients, side effects are mild, transient, and tend to diminish with continued use as the body adjusts to the medication.
Signs of a severe allergic (anaphylactic) reaction including swelling of the face, lips, tongue, or throat; wheezing and coughing (bronchospasm); or severe difficulty breathing. These reactions are very rare but require emergency treatment.
Common Side Effects
May affect up to 1 in 10 users
- Tremor (shaking, particularly of the hands)
- Palpitations (awareness of heartbeat)
- Muscle cramps
- Headache
Uncommon Side Effects
May affect up to 1 in 100 users
- Hypersensitivity reactions (rash, urticaria/hives)
- Very fast heart rate (tachycardia)
- Nervousness or restlessness
Rare Side Effects
May affect up to 1 in 1,000 users
- Decreased blood potassium levels (hypokalemia)
- Dizziness
- Sleep disturbances (insomnia)
Very Rare Side Effects
May affect up to 1 in 10,000 users
- Elevated blood glucose levels (hyperglycemia)
- Joint and muscle pain (arthralgia, myalgia)
- Irregular heartbeat (cardiac arrhythmias, including atrial fibrillation, supraventricular tachycardia, and extrasystoles)
- Chest pain (angina pectoris)
- Irritation of the mouth and throat (oropharyngeal irritation)
- Nausea
- Severe allergic/anaphylactic reaction (swelling of face, lips, tongue, or throat; bronchospasm)
Paradoxical bronchospasm is an important though uncommon adverse reaction that can occur with any inhaled medication. If you experience increased wheezing or breathing difficulty immediately after inhaling Salmeterol Orifarm, discontinue the medication, use your rescue (short-acting) bronchodilator inhaler, and seek medical attention promptly.
The hypokalemic effect of salmeterol is particularly relevant in patients who are concurrently taking other potassium-lowering medications (such as loop or thiazide diuretics, corticosteroids, or theophylline). Low potassium can manifest as muscle weakness, cramps, or irregular heartbeat. Your doctor may order periodic blood tests to monitor your potassium levels if you are considered at risk.
If you experience any side effects not listed here, or if any listed side effect becomes severe or troublesome, inform your doctor, pharmacist, or nurse. Reporting suspected adverse reactions after authorization of a medicine helps to continuously monitor its benefit-risk balance.
How Should You Store Salmeterol Orifarm?
Store Salmeterol Orifarm at or below 25°C (77°F), in a dry place, out of the sight and reach of children. Do not use the inhaler after the expiry date printed on the packaging. Dispose of unused medicine properly through a pharmacy take-back programme—do not flush or discard in household waste.
Proper storage of your inhaler is important to ensure the medication remains effective throughout its shelf life. The inhalation powder is sensitive to moisture, so the device should be kept in a dry environment. Do not store it in the bathroom or other humid locations.
- Temperature: Store below 25°C (77°F). Do not freeze.
- Moisture: Keep the inhaler dry. Close it properly after each use.
- Children: Keep out of the sight and reach of children at all times.
- Expiry date: Check the expiry date (EXP) on the packaging. The expiry date refers to the last day of the indicated month. Do not use the medicine after this date.
- Disposal: Do not throw medicines into wastewater or household waste. Return unused or expired medicines to your pharmacy for proper disposal. This helps protect the environment.
The dose counter on the inhaler will indicate how many doses are remaining. When the numbers 5 to 0 appear in red on the counter, only a few doses are left and you should obtain a replacement inhaler. When the counter shows 0, the device is empty and should be discarded appropriately.
What Does Salmeterol Orifarm Contain?
Each metered dose of Salmeterol Orifarm contains salmeterol xinafoate equivalent to 50 micrograms of salmeterol as the active substance. The only excipient is lactose monohydrate (which contains small amounts of milk proteins).
Salmeterol Orifarm has a deliberately simple formulation, consisting of only the active drug blended with a carrier excipient:
- Active substance: Salmeterol xinafoate, equivalent to 50 micrograms of salmeterol per metered dose. Salmeterol xinafoate is the salt form that allows the drug to be delivered as a stable dry powder.
- Excipient: Lactose monohydrate (contains milk proteins). Lactose acts as a carrier for the micronized drug particles, improving powder flow and ensuring consistent dosing. The amount of lactose per dose is up to 12 mg.
The inhaler device itself is a moulded plastic unit with a mouthpiece and a dose counter. It contains a foil strip with 60 regularly spaced blisters, each holding one premeasured dose of powder. The device is available in packs of 1 × 60 doses or 3 × 60 doses (180 doses total). Not all pack sizes may be marketed in all countries.
The marketing authorisation holder is Orifarm Healthcare A/S, based in Odense, Denmark. The product is manufactured by Orifarm Generics A/S at the same location.
Frequently Asked Questions
Salmeterol and salbutamol (albuterol) are both beta-2 agonist bronchodilators, but they serve different purposes. Salbutamol is a short-acting beta-2 agonist (SABA) that works within minutes and is used as a rescue inhaler for acute asthma symptoms. Salmeterol is a long-acting beta-2 agonist (LABA) with an onset of 10–20 minutes and a duration of 12+ hours, making it suitable for maintenance therapy—not acute relief. Both medications are often used together in an asthma management plan: salmeterol for daily prevention and salbutamol for breakthrough symptoms.
No. Salmeterol Orifarm is a maintenance medication, not a rescue inhaler. It takes 10–20 minutes to start working and is not fast enough to relieve acute bronchospasm. During an asthma attack, you should use a short-acting bronchodilator such as salbutamol (albuterol). If attacks are becoming more frequent, contact your doctor as your treatment plan may need adjustment.
Clinical studies, including the landmark SMART trial and subsequent research, found that using a LABA such as salmeterol without an inhaled corticosteroid (ICS) was associated with a small but significant increase in serious asthma-related events, including hospitalisations and asthma-related deaths. When used in combination with an ICS, this risk is eliminated and outcomes are significantly improved. The ICS controls the underlying airway inflammation, while salmeterol provides sustained bronchodilation. International guidelines (GINA, BTS/SIGN, NAEPP) unanimously recommend that LABAs should never be used as monotherapy in asthma.
The Salmeterol Orifarm inhaler has a built-in dose counter on the top of the device. A full inhaler starts at 60 doses. As you use it, the counter decreases. When the numbers 5 through 0 appear highlighted in red, you have very few doses remaining and should arrange a replacement. When the counter reaches 0, the inhaler is completely empty and should be discarded.
Yes, Salmeterol Orifarm can be used in children aged 4 years and older, at the same dose as adults (50 micrograms twice daily). For children aged 4–6 years, the prescribing doctor must have assessed that the child can use the dry powder inhaler device correctly. Salmeterol Orifarm is not recommended for children under 4 years of age. As with adults, it must always be used alongside an inhaled corticosteroid for asthma treatment.
If you accidentally inhale more doses than prescribed, you may experience tremor, rapid heartbeat, headache, or dizziness. Contact your doctor or local poison control centre for advice. In most cases, symptoms of mild overdose resolve on their own without specific treatment. Do not take additional doses to “catch up” – simply resume your normal schedule at the next planned time.
References
This article is based on the following evidence-based sources, international guidelines, and peer-reviewed publications:
- Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2024 Update. Available at: ginasthma.org
- European Medicines Agency (EMA). Summary of Product Characteristics: Salmeterol xinafoate. EMA product database.
- British National Formulary (BNF). Salmeterol. National Institute for Health and Care Excellence (NICE). Available at: bnf.nice.org.uk
- Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129(1):15-26. doi:10.1378/chest.129.1.15
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. 2023.
- Cates CJ, Jaeschke R, Schmidt S, Ferreira J. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews. 2013;(3):CD006922.
- British Thoracic Society / Scottish Intercollegiate Guidelines Network (BTS/SIGN). British guideline on the management of asthma. SIGN 158. 2019 (updated 2024).
- U.S. Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA review finds no significant increase in risk of serious asthma outcomes with long-acting beta agonists (LABAs) used in combination with inhaled corticosteroids (ICS). 2017.
Editorial Team
This article was written, fact-checked, and medically reviewed by the iMedic Medical Editorial Team, comprising licensed physicians with specialisations in pulmonology, clinical pharmacology, and respiratory medicine.
iMedic Medical Editorial Team – evidence-based content following GRADE framework and international respiratory guidelines (GINA 2024, BTS/SIGN).
iMedic Medical Review Board – independent panel of medical experts ensuring accuracy, completeness, and clinical relevance of all published content.
Evidence level: This article is based on Level 1A evidence (systematic reviews and meta-analyses of randomised controlled trials), regulatory product information (EMA SmPC, FDA labelling), and current international clinical practice guidelines.
Conflict of interest: The iMedic Medical Editorial Team has no conflicts of interest. iMedic receives no funding from pharmaceutical companies and maintains editorial independence.
Last reviewed: